


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|--|--|--|--|
| (51) International Patent Classification ⁶ : C07D 471/06, 498/06, A61K 31/47 // (C07D 471/06, 221:00, 209:00) (C07D 498/06, 263:00, 221:00) | | A1 | (11) International Publication Number: WO 98/40383 (43) International Publication Date: 17 September 1998 (17.09.98) |
| (21) International Application Number: PCT/EP98/01296 (22) International Filing Date: 3 March 1998 (03.03.98) (30) Priority Data: 97200709.0 10 March 1997 (10.03.97) EP (34) Countries for which the regional or international application was filed: DE et al. 97200708.2 10 March 1997 (10.03.97) EP (34) Countries for which the regional or international application was filed: DE et al. (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): VENET, Marc, Gaston [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). ANGIBAUD, Patrick, René [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). LIGNY, Yannick, Aimé, Eddy [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux | | Cedex 9 (FR). PONCELET, Virginie, Sophie [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). SANZ, Gérard, Charles [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. | |
| (54) Title: FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N-OR C-LINKED IMIDAZOLES | | | |
| (57) Abstract | | | |
| This invention concerns compounds of formula (I), the pharmaceutically acceptable acid additions salts and the stereochemically isomeric forms thereof, wherein the dotted line represents an optional bond; X is oxygen or sulfur; -A- is a bivalent radical of formula; R ¹ and R ² each independently are hydrogen, hydroxy, halo, cyano, C ₁ -alkyl, trihalomethyl, trihalomethoxy, C ₂ -alkenyl, C ₁ -alkyloxy, hydroxyC ₁ -alkyloxy, C ₁ -alkyloxyC ₁ -alkyloxy, C ₁ -alkyloxycarbonyl, aminoC ₁ -alkyloxy, mono- or di(C ₁ -alkyl)aminoC ₁ -alkyloxy, Ar, Ar-C ₁ -alkyl, Ar-oxy, Ar-C ₁ -alkyloxy; or when on adjacent positions R ¹ and R ² taken together may form a bivalent radical; R ³ and R ⁴ each independently are hydrogen, halo, cyano, C ₁ -alkyl, C ₁ -alkyloxy, Ar-oxy, C ₁ -alkylthio, di(C ₁ -alkyl)amino, trihalomethyl, trihalomethoxy; or when on adjacent positions R ³ and R ⁴ taken together may form a bivalent radical; R ⁵ is an imidazolyl substituted with hydrogen or C ₁ -alkyl; R ⁶ hydrogen, hydroxy, halo, cyano, optionally substituted C ₁ -alkyl, C ₁ -alkyloxycarbonyl or Ar; or a radical of formula -O-R ⁷ , -S-R ⁸ , -N-R ⁹ ; and Ar is optionally substituted phenyl; having farnesyl transferase inhibiting activity; their preparation, compositions containing them and their use as a medicine. | |  | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


| | | | | | | | |
|----|--------------------------|----|---------------------|----|-----------------------|----|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | Republic of Macedonia | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | IT | Italy | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Congo | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's | NZ | New Zealand | | |
| CM | Cameroon | | Republic of Korea | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE
DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES

- 5 The present invention is concerned with novel 1,8-annelated 2-quinolinone derivatives, the preparation thereof, pharmaceutical compositions comprising said novel compounds and the use of these compounds as a medicine as well as methods of treatment by administering said compounds.
- 10 Oncogenes frequently encode protein components of signal transduction pathways which lead to stimulation of cell growth and mitogenesis. Oncogene expression in cultured cells leads to cellular transformation, characterized by the ability of cells to grow in soft agar and the growth of cells as dense foci lacking the contact inhibition exhibited by non-transformed cells. Mutation and/or overexpression of certain
- 15 oncogenes is frequently associated with human cancer. A particular group of oncogenes is known as *ras* which have been identified in mammals, birds, insects, mollusks, plants, fungi and yeasts. The family of mammalian *ras* oncogenes consists of three major members ("isoforms") : H-*ras*, K-*ras* and N-*ras* oncogenes. These *ras* oncogenes code for highly related proteins generically known as p21^{*ras*}. Once attached
- 20 to plasma membranes, the mutant or oncogenic forms of p21^{*ras*} will provide a signal for the transformation and uncontrolled growth of malignant tumor cells. To acquire this transforming potential, the precursor of the p21^{*ras*} oncoprotein must undergo an enzymatically catalyzed farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide. Therefore, inhibitors of the enzyme that catalyzes this
- 25 modification, farnesyl protein transferase, will prevent the membrane attachment of p21^{*ras*} and block the aberrant growth of *ras*-transformed tumors. Hence, it is generally accepted in the art that farnesyl transferase inhibitors can be very useful as anticancer agents for tumors in which *ras* contributes to transformation.
- 30 Since mutated oncogenic forms of *ras* are frequently found in many human cancers, most notably in more than 50 % of colon and pancreatic carcinomas (Kohl et al., *Science*, vol 260, 1834 - 1837, 1993), it has been suggested that farnesyl tranferase inhibitors can be very useful against these types of cancer.
- 35 In EP-0,371,564 there are described (1*H*-azol-1-ylmethyl) substituted quinoline and quinolinone derivatives which suppress the plasma elimination of retinoic acids. Some of these compounds also have the ability to inhibit the formation of androgens from progestines and/or inhibit the action of the aromatase enzyme complex.

Unexpectedly, it has been found that the present novel compounds, all having a phenyl substituent on the 4-position of the 1,8-annulated 2-quinolinone-moiety bearing a nitrogen- or carbon-linked imidazole, show farnesyl protein transferase inhibiting activity.

The present invention concerns compounds of formula



10

the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein

the dotted line represents an optional bond;

15 X is oxygen or sulfur;

-A- is a bivalent radical of formula

-CH=CH- (a-1),

-CH₂-CH₂- (a-2),

-CH₂-CH₂-CH₂- (a-3),

-CH₂-O- (a-4),

-CH₂-CH₂-O- (a-5),

-CH₂-S- (a-6),

-CH₂-CH₂-S- (a-7),

-CH=N- (a-8),

-N=N- (a-9), or

-CO-NH- (a-10);

20

wherein optionally one hydrogen atom may be replaced by C₁₋₄alkyl or Ar¹;

R¹ and R² each independently are hydrogen, hydroxy, halo, cyano, C₁₋₆alkyl, trihalomethyl, trihalomethoxy, C₂₋₆alkenyl, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, aminoC₁₋₆alkyloxy, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy, Ar², Ar²-C₁₋₆alkyl, Ar²-oxy, Ar²-C₁₋₆alkyloxy; or when on adjacent positions R¹ and R² taken together may form a bivalent radical of formula

25

-O-CH₂-O- (b-1),

-O-CH₂-CH₂-O- (b-2),

-O-CH=CH- (b-3),



30

- O-CH₂-CH₂- (b-4),
 -O-CH₂-CH₂-CH₂- (b-5), or
 -CH=CH-CH=CH- (b-6);

R³ and R⁴ each independently are hydrogen, halo, cyano, C₁-6alkyl, C₁-6alkyloxy, Ar³-oxy, C₁-6alkylthio, di(C₁-6alkyl)amino, trihalomethyl, trihalomethoxy, or when on adjacent positions R³ and R⁴ taken together may form a bivalent radical of formula

- O-CH₂-O- (c-1),
 -O-CH₂-CH₂-O- (c-2), or
 -CH=CH-CH=CH- (c-3);

R⁵ is a radical of formula



- wherein R¹³ is hydrogen, halo, Ar⁴, C₁-6alkyl, hydroxyC₁-6alkyl, C₁-6alkyloxyC₁-6alkyl, C₁-6alkyloxy, C₁-6alkylthio, amino, C₁-6alkyloxycarbonyl, C₁-6alkylS(O)C₁-6alkyl or C₁-6alkylS(O)₂C₁-6alkyl;
 R¹⁴ is hydrogen, C₁-6alkyl or di(C₁-4alkyl)aminosulfonyl;

- R⁶ is hydrogen, hydroxy, halo, C₁-6alkyl, cyano, haloC₁-6alkyl, hydroxyC₁-6alkyl, cyanoC₁-6alkyl, aminoC₁-6alkyl, C₁-6alkyloxyC₁-6alkyl, C₁-6alkylthioC₁-6alkyl, aminocarbonylC₁-6alkyl, C₁-6alkyloxycarbonylC₁-6alkyl, C₁-6alkylcarbonyl-C₁-6alkyl, C₁-6alkyloxycarbonyl, mono- or di(C₁-6alkyl)aminoC₁-6alkyl, Ar⁵, Ar⁵-C₁-6alkyloxyC₁-6alkyl; or a radical of formula



wherein R⁷ is hydrogen, C₁-6alkyl, C₁-6alkylcarbonyl, Ar⁶, Ar⁶-C₁-6alkyl, C₁-6alkyloxycarbonylC₁-6alkyl, or a radical of formula -Alk-OR¹⁰ or -Alk-NR¹¹R¹²;

R⁸ is hydrogen, C₁-6alkyl, Ar⁷ or Ar⁷-C₁-6alkyl;

R⁹ is hydrogen, C₁-6alkyl, C₁-6alkylcarbonyl, C₁-6alkyloxycarbonyl, C₁-6alkylaminocarbonyl, Ar⁸, Ar⁸-C₁-6alkyl, C₁-6alkylcarbonyl-C₁-6alkyl, Ar⁸-carbonyl, Ar⁸-C₁-6alkylcarbonyl, aminocarbonylcarbonyl, C₁-6alkyloxyC₁-6alkylcarbonyl, hydroxy, C₁-6alkyloxy, aminocarbonyl, di(C₁-6alkyl)aminoC₁-6alkylcarbonyl, amino, C₁-6alkylamino,

C₁₋₆alkylcarbonylamino, or a radical or formula -Alk-OR¹⁰ or -Alk-NR¹¹R¹²;

wherein Alk is C₁₋₆alkanediyl;

R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, hydroxyC₁₋₆alkyl, Ar⁹ or Ar⁹-C₁₋₆alkyl;

R¹¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, Ar¹⁰ or Ar¹⁰-C₁₋₆alkyl;

R¹² is hydrogen, C₁₋₆alkyl, Ar¹¹ or Ar¹¹-C₁₋₆alkyl; and

Ar¹ to Ar¹¹ are each independently selected from phenyl; or phenyl substituted with halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trifluoromethyl.

R¹³ may also be bound to one of the nitrogen atoms in the imidazole ring of formula (d-1). In that case the meaning of R¹³ when bound to the nitrogen is limited to hydrogen, Ar⁴, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylS(O)-C₁₋₆alkyl or C₁₋₆alkylS(O)₂C₁₋₆alkyl.

As used in the foregoing definitions and hereinafter, halo is generic to fluoro, chloro, bromo and iodo; C₁₋₄alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, e.g. methyl, ethyl, propyl, butyl, 1-methylethyl, 2-methylpropyl and the like; C₁₋₆alkyl includes C₁₋₄alkyl and the higher homologues thereof having 5 to 6 carbon atoms such as, for example, pentyl, 2-methylbutyl, hexyl, 2-methylpentyl and the like; C₁₋₆alkanediyl defines bivalent straight and branched chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms, such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the branched isomers thereof; C₂₋₆alkenyl defines straight and branched chain hydrocarbon radicals containing one double bond and having from 2 to 6 carbon atoms such as, for example, ethenyl, 2-propenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl, and the like. The term "S(O)" refers to a sulfoxide and "S(O)₂" to a sulfon.

The pharmaceutically acceptable acid addition salts as mentioned hereinabove are meant to comprise the therapeutically active non-toxic acid addition salt forms which the compounds of formula (I) are able to form. The compounds of formula (I) which have basic properties can be converted in their pharmaceutically acceptable acid addition salts by treating said base form with an appropriate acid. Appropriate acids comprise, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such

as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic (*i.e.* butanedioic acid), maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, *p*-toluenesulfonic, cyclamic, salicylic, *p*-amino-salicylic, pamoic and the like acids.

5

The term acid addition salts also comprises the hydrates and the solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

- 10 The term stereochemically isomeric forms of compounds of formula (I), as used hereinbefore, defines all possible compounds made up of the same atoms bonded by the same sequence of bonds but having different three-dimensional structures which are not interchangeable, which the compounds of formula (I) may possess. Unless otherwise mentioned or indicated, the chemical designation of a compound encompasses the
- 15 mixture of all possible stereochemically isomeric forms which said compound may possess. Said mixture may contain all diastereomers and/or enantiomers of the basic molecular structure of said compound. All stereochemically isomeric forms of the compounds of formula (I) both in pure form or in admixture with each other are intended to be embraced within the scope of the present invention.

20

Some of the compounds of formula (I) may also exist in their tautomeric forms. Such forms although not explicitly indicated in the above formula are intended to be included within the scope of the present invention.

- 25 Wherever -A- is a bivalent radical of formula (a-4), (a-5), (a-6), (a-7) or (a-8) the CH₂ or CH moiety in said bivalent radical is preferably connected to the nitrogen atom of the 2-quinolinone-moiety of the compounds of formula (I) or the intermediates of formula (II), (IV), (VI) and (VII).

- 30 Whenever used hereinafter, the term "compounds of formula (I)" is meant to include also the pharmaceutically acceptable acid addition salts and all stereoisomeric forms.

A group of interesting compounds consists of those compounds of formula (I) wherein one or more of the following restrictions apply :

- 35 a) the dotted line represents an optional bond;
b) X is O or S;

- c) R^1 and R^2 are each independently selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} alkyloxy, trihalomethyl or trihalomethoxy; in particular hydrogen, halo or C_{1-4} alkyl;
- d) R^3 and R^4 are each independently selected from hydrogen, halo, C_{1-6} alkyl, C_{1-6} alkyloxy, trihalomethyl or trihalomethoxy; in particular hydrogen, halo, C_{1-4} alkyl or C_{1-4} alkyloxy;
- e) R^5 is a radical of formula (d-1) wherein R^{13} is hydrogen or C_{1-6} alkyl; or R^5 is a radical of formula (d-2) wherein R^{13} is hydrogen or C_{1-6} alkyl and R^{14} is hydrogen or C_{1-6} alkyl;
- f) R^6 is hydrogen, hydroxy, halo C_{1-6} alkyl, hydroxy C_{1-6} alkyl, cyano C_{1-6} alkyl, C_{1-6} alkyloxycarbonyl C_{1-6} alkyl, or a radical of formula $-NR^8R^9$ wherein R^8 is hydrogen or C_{1-6} alkyl and R^9 is hydrogen, C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxy- C_{1-6} alkylcarbonyl; in particular R^6 is hydrogen, hydroxy, halo or a amino;
- g) -A- is (a-1), (a-2), (a-3), (a-4), (a-5), (a-8), (a-9) or (a-10).

A particular group of compounds consists of those compounds of formula (I) wherein the dotted line represents a bond; X is O or S; R^2 is hydrogen and R^1 is halo, preferably chloro, especially 3-chloro; R^4 is hydrogen and R^3 is halo, preferably chloro, especially 4-chloro; R^5 is a radical of formula (d-1) wherein R^{13} is hydrogen or C_{1-4} alkyl; and R^6 is hydrogen.


Another particular group of compounds consists of those compounds of formula (I) wherein the dotted line represent a bond; X is O or S; R^2 is hydrogen and R^1 is halo, preferably chloro, especially 3-chloro; and R^4 is hydrogen and R^3 is halo, preferably chloro, especially 4-chloro; R^5 is a radical of formula (d-2) wherein R^{13} is hydrogen or C_{1-4} alkyl and R^{14} is hydrogen or C_{1-4} alkyl; R^6 is hydrogen, hydroxy, halo or amino.

Preferred compounds are those compounds of formula (I) wherein the dotted line represents a bond; X is oxygen; R^1 is 3-chloro; R^2 is hydrogen; R^3 is 4-chloro; R^4 is hydrogen; R^5 is a radical of formula (d-1) wherein R^{13} is hydrogen or C_{1-4} alkyl; R^6 is hydrogen, and -A- is (a-1), (a-2) or (a-3).


Other preferred compounds are those compounds of formula (I) wherein the dotted line represent a bond; X is oxygen; R^1 is 3-chloro; R^2 is hydrogen; R^3 is 4-chloro; R^4 is hydrogen; R^5 is a radical of formula (d-2) wherein R^{13} is hydrogen and R^{14} is C_{1-4} alkyl; R^6 is amino; and -A- is (a-1), (a-2) or (a-3).

The most preferred compounds of formula (I) are
 7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-2,3-dihydro-1*H*,5*H*-
 benzo[*ij*]quinolizin-5-one,
 7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-1,2-dihydro-4*H*-
 5 pyrrolo[3,2,1-*ij*]quinoline-4-one,
 8-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-6-(3-chlorophenyl)-1,2-
 dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-4-one, and
 8-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-6-(3-chlorophenyl)-2,3-
 dihydro-1*H*,5*H*-benzo[*ij*]quinolizin-5-one; the stereoisomeric forms and the
 10 pharmaceutically acceptable acid addition salts thereof.


The compounds of formula (I), wherein R^6 is hydroxy and R^5 is a radical of formula
 (d-2) wherein R^{14} is C_{1-6} alkyl, said compounds being referred to as compounds of
 formula (I-a-1) may be prepared by reacting an intermediate ketone of formula (II) with
 15 a intermediate of formula (III-1). Said reaction requires the presence of a suitable
 strong base, such as, for example, butyl lithium in an appropriate solvent, such as, for
 example, tetrahydrofuran, and the presence of an appropriate silanederivative, such as,
 for example, triethylchlorosilane. During the work-up procedure an intermediate silane
 derivative is hydrolyzed. Other procedures with protective groups analogous to
 20 silanederivatives can also be applied.



- Also, the compounds of formula (I), wherein R^6 is hydroxy and R^5 is a radical of formula (d-2) wherein R^{14} is hydrogen, said compounds being referred to as compounds of formula (I-a-2) may be prepared by reacting an intermediate ketone of formula (II) with a intermediate of formula (III-2), wherein PG is a protective group such as, for example, a sulfonyl group, e.g. a dimethylamino sulfonyl group, which can be removed after the addition reaction. Said reaction is conducted analogously as for the preparation of compounds of formula (I-a-1), followed by removal of the protecting group PG, yielding compounds of formula (I-a-2).
- Compounds of formula (I-g), defined as compounds of formula (I) wherein R^5 represents a radical of formula (d-1), can be prepared by *N*-alkylating an intermediate of formula (XVIII) with an intermediate of formula (XVII), wherein W is an appropriate leaving group such as, for example, chloro, bromo, methanesulfonyloxy or benzenesulfonyloxy. The reaction can be performed in a reaction-inert solvent such as, for example, acetonitrile, and optionally in the presence of a suitable base such as, for example, sodium carbonate, potassium carbonate or triethylamine. Stirring may enhance the rate of the reaction. The reaction may conveniently be carried out at a temperature ranging between room temperature and the reflux temperature of the reaction mixture.



Also, compounds of formula (I-g) can be prepared by *N*-alkylating an intermediate of formula (XIX), wherein Y is carbon or sulfur, such as, for example, a 1,1'-carbonyl-diimidazole, with an intermediate of formula (XVI).




Said reaction may conveniently be conducted in a reaction-inert solvent, such as, e.g. tetrahydrofuran, optionally in the presence of a base, such as sodium hydride, and at a temperature ranging between room temperature and the reflux temperature of the reaction mixture.

5

Compounds of formula (I-g) may also be prepared by reacting an intermediate of formula (XVII) with ammonia and subsequent treatment with isothiocyanate as described in EP-0,293,978 page 12, line 33 to page 13, line 20.


- 10 The compounds of formula (I-a) can be converted to compounds of formula (I-b), defined as a compound of formula (I) wherein R^6 is hydrogen, by submitting the compounds of formula (I-a) to appropriate reducing conditions, such as, e.g. stirring in acetic acid in the presence of formamide.




15

Further, compounds of formula (I-a) can be converted to compounds of formula (I-c) wherein R^6 is halo, by reacting the compounds of formula (I-a) with a suitable halogenating agent, such as, e.g. thionyl chloride or phosphorus tribromide.


- 20 Successively, the compounds of formula (I-c) can be treated with a reagent of formula $H-NR^8R^9$ in a reaction-inert solvent, thereby yielding compounds of formula (I-d).



A compound of formula (I-f), defined as a compound of formula (I) wherein X is sulfur, may be prepared by reacting the corresponding compound of formula (I-e), defined as a compound of formula (I) wherein X is oxygen, with a reagent like phosphorus pentasulfide or Lawesson's reagent in a suitable solvent such as, for example, pyridine.




An intermediate of formula (II-b), defined as an intermediate of formula (II) wherein the dotted line represents a bond, can be prepared by oxidizing an intermediate of formula (II-a), defined as intermediates of formula (II) wherein the dotted line does not represent a bond, following art-known oxidation methods such as, for example, treatment with bromine in an appropriate solvent such as, e.g. bromobenzene, or treatment with iodine in the presence of acetic acid and potassium acetate.




15 Said oxidation reaction can give rise to side-products wherein the bivalent radical -A- is oxidized. For instance, oxidation of intermediates of formula (II-a) wherein -A- is (a-2) may give intermediates of formula (II-b) wherein -A- is (a-1).

20 Intermediates of formula (XVI) wherein R⁶ is hydrogen, said compounds being represented by formula (XVI-a), can be prepared by reacting intermediates of formula (II) with an appropriate reducing agent such as, e.g. sodium borohydride, in a suitable solvent such as, e.g. methanol. Optionally, intermediates of formula (XVI) may be converted to intermediates of formula (XVII) wherein R⁶ is hydrogen, said compounds being represented by formula (XVII-a), by treating (XVI-a) with a suitable reagent such

as, e.g. methanesulfonyloxy chloride, or a halogenating reagent such as, e.g. POCl₃ or SOCl₂.




- 5 Intermediates of formula (II-a) can be prepared by reacting intermediates of formula (IV) with intermediates of formula (V) in the presence of polyphosphoric acid (PPA), at a temperature ranging between room temperature and the reflux temperature of the reaction mixture. Optionally said reaction may be performed in a reaction-inert solvent.




10

- Alternatively, an intermediate of formula (II-a) can be made in a two-step synthesis by cyclizing an intermediate of formula (IV) in the presence of polyphosphoric acid (PPA) and subsequent treating the thus obtained intermediate (VI) with an intermediate of formula (VIII) in the presence of PPA. Said two-step synthesis may be conducted in a "one-pot" synthesis or, if desired, intermediates of formula (VI) may be isolated and purified before reaction with intermediates of formula (V).





Intermediates of formula (IV) can be prepared by treating intermediates of formula (VIII), wherein X is oxygen or sulfur and Z is hydroxy or halo, with an intermediate of formula (VII) in a reaction-inert solvent such as, e.g. dichloromethane, and in the presence of a base such as, e.g. triethylamine, to pick up the acid liberated during the reaction.



Intermediates of formula (II-b-1), being intermediates of formula (II-b) wherein X is oxygen and -A'- is a bivalent radical of formula (a-4) or (a-5), can be prepared starting from an intermediate of formula (IX). Said intermediates (IX) are conveniently prepared by protecting the corresponding art-known ketones. Intermediates of formula (IX) are stirred with intermediates of formula (X) in the presence of a base such as sodium hydroxide, in an appropriate solvent, such as an alcohol, e.g. methanol. The thus obtained intermediates of formula (XI) are converted to intermediates of formula (XII) in the presence of a suitable reagent such as, an acid, e.g. TiCl₃, in the presence of water; or by hydrogenation under acidic conditions in the presence of a suitable catalyst e.g. platinum on carbon; and by subsequent treatment with acetic anhydride.

Intermediates of formula (XII) undergo ring closure in the presence of a base such as, for example, potassium *tert*-butoxide, and subsequently hydrolysis, yielding intermediates of formula (XIII). After conversion of the methoxy group of intermediates of formula (XVIII) into hydroxy, by treatment with a suitable agent such as, e.g. borontribromide, the intermediates of formula (XIV) are treated with an intermediate of formula (XV), wherein A' is a bivalent radical of formula (a-4) or (a-5), thereby yielding intermediates of formula (II-b-1).





- 5 The compounds of formula (I) and some of the intermediates have at least one stereogenic center in their structure. This stereogenic center may be present in a R or a S configuration.

10 The compounds of formula (I) as prepared in the hereinabove described processes are generally racemic mixtures of enantiomers which can be separated from one another following art-known resolution procedures. The racemic compounds of formula (I) may be converted into the corresponding diastereomeric salt forms by reaction with a suitable chiral acid. Said diastereomeric salt forms are subsequently separated, for example, by selective or fractional crystallization and the enantiomers are liberated

15 therefrom by alkali. An alternative manner of separating the enantiomeric forms of the compounds of formula (I) involves liquid chromatography using a chiral stationary phase. Said pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically. Preferably if a specific

20 stereoisomer is desired, said compound will be synthesized by stereospecific methods of preparation. These methods will advantageously employ enantiomerically pure starting materials.

25 The compounds of formula (I), the pharmaceutically acceptable acid addition salts and stereoisomeric forms thereof have valuable pharmacological properties in that they

inhibit farnesyl protein transferase (FPTase), as can be evidenced by the results obtained in the pharmacological examples C-1 and C-2.

Furthermore, it is believed that the compounds of formula (I) wherein R⁵ is a radical of formula (d-2) can also inhibit geranylgeranyltransferase (GGTase).

This invention provides a method for inhibiting the abnormal growth of cells, including transformed cells, by administering an effective amount of a compound of the invention. Abnormal growth of cells refers to cell growth independent of normal regulatory mechanisms (e.g. loss of contact inhibition). This includes the abnormal growth of : (1) tumor cells (tumors) expressing an activated *ras* oncogene; (2) tumor cells in which the *ras* protein is activated as a result of oncogenic mutation of another gene; (3) benign and malignant cells of other proliferative diseases in which aberrant *ras* activation occurs. Furthermore, it has been suggested in literature that *ras* oncogenes not only contribute to the growth of tumors *in vivo* by a direct effect on tumor cell growth but also indirectly, *i.e.* by facilitating tumor-induced angiogenesis (Rak. J. et al, *Cancer Research*, 55, 4575-4580, 1995). Hence, pharmacologically targeting mutant *ras* oncogenes could conceivably suppress solid tumor growth *in vivo*, in part, by inhibiting tumor-induced angiogenesis.

This invention also provides a method for inhibiting tumor growth by administering an effective amount of a compound of the present invention, to a subject, e.g. a mammal (and more particularly a human) in need of such treatment. In particular, this invention provides a method for inhibiting the growth of tumors expressing an activated *ras* oncogene by the administration of an effective amount of the compounds of the present invention. Examples of tumors which may be inhibited, but are not limited to, lung cancer (e.g. adenocarcinoma), pancreatic cancers (e.g. pancreatic carcinoma such as, for example exocrine pancreatic carcinoma), colon cancers (e.g. colorectal carcinomas, such as, for example, colon adenocarcinoma and colon adenoma), hematopoietic tumors of lymphoid lineage (e.g. acute lymphocytic leukemia, B-cell lymphoma, Burkitt's lymphoma), myeloid leukemias (for example, acute myelogenous leukemia (AML)), thyroid follicular cancer, myelodysplastic syndrome (MDS), tumors of mesenchymal origin (e.g. fibrosarcomas and rhabdomyosarcomas), melanomas, teratocarcinomas, neuroblastomas, gliomas, benign tumor of the skin (e.g. keratoacanthomas), breast carcinoma, kidney carcinoma, ovary carcinoma, bladder carcinoma and epidermal carcinoma.

This invention may also provide a method for inhibiting proliferative diseases, both benign and malignant, wherein *ras* proteins are aberrantly activated as a result of oncogenic mutation in genes, i.e. the *ras* gene itself is not activated by mutation to an oncogenic form, with said inhibition being accomplished by the administration of an effective amount of the compounds described herein, to a subject in need of such a treatment. For example, the benign proliferative disorder neurofibromatosis, or tumors in which *ras* is activated due to mutation or overexpression of tyrosine kinase oncogenes may be inhibited by the compounds of this invention.

Hence, the present invention discloses the compounds of formula (I) for use as a medicine as well as the use of these compounds of formula (I) for the manufacture of a medicament for treating one or more of the above mentioned conditions.

In view of their useful pharmacological properties, the subject compounds may be formulated into various pharmaceutical forms for administration purposes.

To prepare the pharmaceutical compositions of this invention, an effective amount of a particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, to aid solubility for example, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier

optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

Those skilled in the art could easily determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective amount would be from 0.01 mg/kg to 100 mg/kg body weight, and in particular from 0.05 mg/kg to 10 mg/kg body weight. It may be appropriate to administer the required dose as two, three, four or more sub-doses at appropriate intervals throughout the day. Said sub-doses may be formulated as unit dosage forms, for example, containing 0.5 to 500 mg, and in particular 1 mg to 200 mg of active ingredient per unit dosage form.

The following examples are provided for purposes of illustration.

Experimental part

Hereinafter "ACN" means acetonitrile, "THF" means tetrahydrofuran, "DIPE" means diisopropylether, "DCM" means dichloromethane and "DMF" means *N,N*-dimethylformamide.

Of some compounds of formula (I) the absolute stereochemical configuration was not experimentally determined. In those cases the stereochemically isomeric form which was first isolated is designated as "A" and the second as "B", without further reference to the actual stereochemical configuration.

A. Preparation of the intermediates.

Example A.1

Triethylamine (9.2 ml) was added at room temperature to a solution of indoline (20 g) in DCM (200 ml) and the mixture was cooled till 5°C. A solution of *m*-chloro-cinnamoyl chloride (40 g) in DCM (100 ml) was added dropwise and the mixture was stirred at room temperature for 48 hours. Water was added, the organic layer was decanted, washed with water, dried, filtered off and evaporated. The residue was purified by column chromatography over silica gel (eluent : cyclohexane/ethyl acetate 90/10), yielding 41 g (73%) of 1-[3-(3-chlorophenyl)-1-oxo-2-propenyl]-2,3-dihydro-1*H*-indole (interm. 37).

In a similar way, 1-[3-(3-chlorophenyl)-1-oxo-2-propenyl]-1,2,3,4-tetrahydroquinoline (interm. 38) was synthesized.

Example A.2

Intermediate 37 (40 g) and polyphosphoric acid (350 g) were stirred and heated at 140°C for 16 hours. 4-Chlorobenzoic acid (44 g) was added and the solution was stirred and heated at 140°C for 2 hours and 30 minutes. The mixture was cooled till 80°C, ice was added carefully and the mixture was brought till room temperature. The precipitate was filtered off, washed with water and basified with an aqueous ammonia solution. The precipitate was taken up in DCM and filtered off. The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 99.5/0.5 to 99/1), yielding 12 g (20%) of (±)-8-(4-chlorobenzoyl)-6-(3-chlorophenyl)-1,2,5,6-tetrahydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-4-one (interm. 11).

In a similar way, (±)-9-(4-chlorobenzoyl)-7-(3-chlorophenyl)-2,3,6,7-tetrahydro-1*H*,5*H*-benzo[*ij*]quinolizin-5-one (interm. 8) was synthesized.

Example A.3

A mixture of bromine (4.2 ml) in bromobenzene (80 ml) was added dropwise at room temperature to a solution of intermediate 11 (34.2 g) in bromobenzene (300 ml). The mixture was stirred and refluxed overnight. The mixture was cooled to room temperature and basified with an aqueous ammonia solution. The solvent was evaporated. The residue was partitioned between DCM and water. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : DCM). Two fractions were collected, yielding 16 g of 8-(4-chlorobenzoyl)-6-(3-chlorophenyl)-1,2-dihydro-4*H*-

pyrrolo[3,2,1-ij]quinolin-4-one (intermediate 24) and 2.1 g (6.2%) of 8-(4-chlorobenzoyl)-6-(3-chlorophenyl)-4*H*-pyrrolo[3,2,1-ij]quinolin-4-one (interm. 25).

Example A.4

- 5 A mixture of intermediate (9) (20.9 g), iodine (32.8 g) and potassium acetate (19 g) in acetic acid (150 ml) was stirred at 130°C for 3 days. The mixture was poured out warm on ice and NaHSO₃ and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 99/1 to 97/3). The pure
- 10 fractions were collected and the solvent was evaporated. The residue was taken up in diethyl ether, filtered off and dried, yielding 16.9 g (81%) of 8-(4-chlorobenzoyl)-1,2-dihydro-6-phenyl-4*H*-pyrrolo[3,2,1-ij]quinolin-4-one (interm. 21).

Example A.5

- 15 a) A mixture of (4-chlorophenyl)(3-methoxy-4-nitrophenyl)methanone (40.7 g), 1,2-ethanediol (31.2 ml) and 4-methylbenzene sulfonic acid (5.31 g) in methylbenzene (320 ml) was stirred and refluxed using a Dean-Stark apparatus. The mixture was washed with K₂CO₃ (10%) and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was crystallized from DIPE.
- 20 The precipitate was filtered off and dried, yielding 22.48 g (50.4%) of 2-(4-chlorophenyl)-2-(3-methoxy-4-nitrophenyl)-1,3-dioxolane (interm. 39).
- b) Intermediate (39) (22.48 g) and 3-chlorobenzenecetonitrile (15 ml) were added to a solution of sodium hydroxide (11.25 g) in methanol (91 ml). The mixture was stirred and refluxed for 24 hours. Ice water was added. The precipitate was filtered off,
- 25 washed with water and with ethanol and dried. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/cyclohexane 60/40). The pure fractions were collected and the solvent was evaporated, yielding 8.5 g (27.3%) of 3-(3-chlorophenyl)-5-[2-(4-chlorophenyl)-1,3-dioxolan-2-yl]-7-methoxy-2,1-benzisoxazole (interm. 40).
- 30 c) A mixture of intermediate (40) (14 g) in HCl conc. (3.5 ml) and THF (140 ml) was hydrogenated under a 2.4×10^5 Pa (2.4 bar) pressure for 6 hours with platinum on carbon (5%; 1.4 g) as a catalyst in the presence of a 10% solution of thiophene in methanol (0.35 ml). After uptake of adequate H₂, the catalyst was filtered through celite and the filtrate was evaporated till dryness. The residue was taken up in 2-propanone and
- 35 DIPE. The precipitate was filtered off and dried, yielding 11.8 g (84.3%) of [2-amino-5-(4-chlorobenzoyl)-3-methoxyphenyl](3-chlorophenyl)methanone (interm. 41).

- d) A mixture of intermediate (41) (11.7 g) and acetic anhydride (28 ml) in toluene (150 ml) was stirred and refluxed for 24 hours. The solvent was evaporated till dryness. The product was used without further purification, yielding 14.5g of *N*-acetyl-*N*-[2-(3-chlorobenzoyl)-4-(4-chlorobenzoyl)-6-methoxyphenyl]acetamide (interm. 42)
- 5 e) Potassium-*tert*-butoxide (13.5 g) was added portionwise to a mixture of intermediate (42) (14.5 g) in dimethyl ether (150ml). The mixture was stirred at room temperature for 16 hours and then hydrolized. The solvent was evaporated. Water was added. The mixture was extracted with DCM and decanted. The organic layer was dried, filtered and the solvent was evaporated till dryness, yielding 11g (86.6%) of
- 10 6-(4-chlorophenyl)-4-(3-chlorophenyl)-8-methoxy-2(1*H*)-quinolinone (interm. 43).
- f) A boron tribromide solution in DCM (1M; 95 ml) was added dropwise at 0°C to a mixture of intermediate (43) (10 g) in DCM (100 ml). The mixture was stirred at room temperature overnight, then hydrolized, alkalized with K₂CO₃ (10%) and extracted with CH₂Cl₂/CH₃OH 90/10. The organic layer was separated, dried, filtered and the
- 15 solvent was evaporated till dryness. The product was used without further purification, yielding 9.6 g of 6-(4-chlorophenyl)-4-(3-chlorophenyl)-8-hydroxy-2(1*H*)-quinolinone (interm. 44)
- g) A mixture of intermediate (44) (15 g), 1,2-dibromoethane (12.6 ml), potassium carbonate (20.2 g) and tricaprylylmethylammonium chloride (Aliquat 336) (1.6 ml) in
- 20 ACN (120 ml) and DCM (180 ml) was stirred at 50°C for 24 hours and then cooled to room temperature. Water was added. The mixture was decanted and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/EtOAc 95/5). Two pure fractions were collected and their solvents
- 25 were evaporated, yielding 4.5 g (28.6%) of 9-(4-chlorophenyl)-7-(3-chlorophenyl)-2,3-dihydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazin-5-one (interm. 45).
- h) Sodium borohydride (NaBH₄) (0.21 g) was added at 5°C to a mixture of intermediate (45) (2.5 g) in methanol (30 ml) and THF (30 ml). The mixture was stirred at 5°C for 30 minutes, then hydrolized, extracted with DCM and decanted. The
- 30 organic layer was dried, filtered and the solvent was evaporated till dryness, yielding 2.3 g of (±)-7-(3-chlorophenyl)-9-[(4-chlorophenyl)hydroxymethyl]-2,3-dihydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazin-5-one (interm. 46).
- i) A mixture of intermediate (46) (2.3 g) in thionylchloride (30 ml) was stirred at room temperature for 16 hours. The solvent was evaporated till dryness. The product was
- 35 used without further purification, yielding 2.6 g of (±)-9-[chloro(4-chlorophenyl)-

methyl]-7-(3-chlorophenyl)-2,3-dihydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazin-5-one (intermediate 47).

In a similar way, (±)-8-[chloro(4-chlorophenyl)methyl]-6-(3-chlorophenyl)-2*H*,4*H*-oxazolo[5,4,3-*ij*]quinolin-4-one (interm. 48) was also prepared.

5

Example A.6

Intermediate (37) (23 g) and polyphosphoric acid (PPA) (120 g) were stirred at 140°C for 24 hours. The mixture was poured out into ice water, filtered, washed with water, stirred in NH₃ (aq.), washed with water and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : DCM). The pure fractions were collected and the solvent was evaporated. Part of this fraction was crystallized from diethyl ether/2-propanone. The precipitate was filtered off and dried, yielding 0.6 g of (±)-6-(3-chlorophenyl)-1,2,5,6-tetrahydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-4-one (interm. 3).

15

Example A.7

a) Pyridine (25 ml) was added to a mixture of 3,4-dihydro-2*H*-1,4-benzoxazine (17.8 g) in DCM (200 ml). The mixture was cooled on an ice bath and poured out into a mixture of *m*-chloro-cinnamoyl chloride (33 g) in DCM (100 ml). The mixture was stirred at room temperature overnight. Water was added and the mixture was decanted. The organic layer was dried, filtered and the solvent was evaporated till dryness, to give a residue which was purified by column chromatography over silica gel (eluent : cyclohexane/ethyl acetate 80/20) and recrystallisation from ACN/diethyl ether, yielding 26g (65.8%) of 4-[3-(3-chlorophenyl)-1-oxo-2-propen-1-yl]-2,3-dihydro-4*H*-1,4-benzoxazine (interm. 51).

b) AlCl₃ (7.2 g) was added to a mixture of intermediate (51) (5 g) in chlorobenzene (50 ml). The mixture was stirred and refluxed at 80°C for 2 hours, then poured out on ice and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was taken up in DCM, filtered off, washed with CH₂Cl₂/diethyl ether and dried, to give a residue which was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH 99/1), yielding 3.4 g (62%) of (±)-7-(3-chlorophenyl)-2,3,6,7-tetrahydro-5*H*-pyrido[1,2,3-*de*]-1,4-benzoxazin-5-one (interm. 7).

30

Example A.8

- a) Butyllithium (1.6 M in hexanes, 22.4 ml) was added at -70°C under nitrogen flow to a mixture of 1-methylimidazole (2.94 g) in THF (50 ml). The mixture was stirred at
5 -70°C for 30 minutes. Triethylsilyl chloride (6 ml) was added. The mixture was brought to room temperature and cooled to -70°C. Butyllithium (1.6 M in hexanes, 22.4 ml) was added. The mixture was stirred at -70°C for 1 hour, then brought to -15°C and cooled to -70°C. Intermediate 12 (3.8 g) was added portionwise. The mixture was brought to -10°C. Water was added and the mixture was extracted with ethyl acetate
10 and a small amount of methanol. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.2). The pure fractions were collected and the solvent was evaporated, yielding 4 g (88%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-8-methoxy-2(1*H*)-
15 quinolinone (interm. 49).
- b) A boron tribromide solution in DCM (1M; 27.6 ml) was added dropwise at 10°C to a solution of intermediate (49) (2.8 g) in DCM (30 ml). The mixture was stirred at room temperature for 5 hours. Water was added slowly. The mixture was stirred at room temperature overnight. The precipitate was filtered off, washed with water and dried,
20 yielding 2.9 g (100%) of (±)-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-8-hydroxy-2(1*H*)-quinolinone (interm. 50).

Example A.9

- Sodium borohydride (0.51 g) was added portionwise at room temperature to a solution
25 of intermediate (23) (2.9 g) in methanol (20 ml) and THF (10 ml) and the mixture was stirred at room temperature for 1 hour. The mixture was poured into water and evaporated. Methanol was added, the mixture was extracted with DCM and decanted. The organic layer was dried, filtered and evaporated, yielding 2.9 g (100%) of (±)-7-(3-chlorophenyl)-9-[hydroxy(4-chlorophenyl)methyl]-2,3-dihydro-1*H*,5*H*-benzo[*ij*]-
30 quinolizin-5-one (interm. 52).
- In a similar way, (±)-7-(3-chlorophenyl)-9-[hydroxy(4-chlorophenyl)methyl]-2,3,6,7-tetrahydro-1*H*,5*H*-benzo[*ij*]quinolizin-5-one (interm. 53) was synthesized.

Example A.10

- 35 Methanesulfonyl chloride (1.6 ml) was added dropwise at room temperature to a solution of intermediate (52) (2.6 g) and triethylamine (4.1 ml) in DCM (30 ml) and the mixture was stirred at room temperature for 2 hours. The mixture was poured into

water and decanted. The organic layer was dried, filtered and evaporated, yielding 3.4 g of (±)-7-(3-chlorophenyl)-9-[hydroxy(4-chlorophenyl)methyl]-2,3,6,7-tetrahydro-1*H*,5*H*-benzo[*ij*]quinolizin-5-one (interm. 54).

5 Example A.11

- a) 1,1'-Carbonyldiimidazole (41 g) was added portionwise at room temperature to a mixture of 2-amino-5-bromo-3-nitro-benzoic acid (55 g) in DCM (700 ml). The mixture was stirred at room temperature for 1 hour. *N*-methoxy-methanamine hydrochloride (24.6 g) was added. The mixture was stirred at room temperature
10 overnight and hydrolyzed with water. The precipitate was filtered off and the filtrate was decanted. The organic layer was dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/ethyl acetate 98/2). The pure fractions were collected and the solvent was evaporated. The precipitate was taken up in HCl 3N (250 ml). The mixture was stirred
15 at room temperature for 4 hours. The precipitate was filtered off, washed with water and dried, yielding 23 g of 2-amino-5-bromo-*N*-methoxy-*N*-methyl-3-nitrobenzamide (interm. 55, mp. 129°C)
- b) A mixture of 1-bromo-3-chlorophenyl (37.3 ml) in THF (300 ml) was added dropwise to a mixture of magnesium (7.7 g) in a small amount of THF, while the
20 temperature was kept at 50°C-60°C. The mixture was stirred at room temperature for 1 hour and cooled to 5°C. A mixture of intermediate (55) (30.7 g) in THF (300 ml) was added dropwise. The mixture was stirred at 5°C for 15 minutes, hydrolyzed, extracted with ethyl acetate, filtered over celite and decanted. The organic layer was dried, filtered and the solvent was evaporated till dryness. The residue was purified by column
25 chromatography over silica gel (eluent: CH₂Cl₂/cyclohexane 50/50). The pure fractions were collected and the solvent was evaporated, yielding 17.5 g (46.4%) of (2-amino-5-bromo-3-nitrophenyl)(3-chlorophenyl)methanone (interm. 56, mp. 134°C).
- c) TiCl₃ (15% in H₂O, 400 ml) was added at room temperature to a solution of intermediate (56) (16 g) in THF (230 ml). The mixture was stirred at room temperature
30 overnight. Water was added and the mixture was extracted twice with DCM. The combined organic layer was washed with K₂CO₃ 10%, dried, filtered and the solvent was evaporated, yielding 18 g of (2,3-diamino-5-bromophenyl)(3-chlorophenyl)-methanone (interm. 57)
- d) A mixture of interm. (57) (18 g) and acetic acid anhydride (19 ml) in toluene (400
35 ml) was stirred and refluxed for 4 hours and then allowed to cool to room temperature.

The precipitate was filtered off, washed with DIPE and dried, yielding 13.2 g (90%) of *N,N*-[5-bromo-3-(3-chlorobenzoyl)-1,2-phenylene]diacetamide (interm. 58).

5 e) Potassium *tert*-butoxide (18 g) was added at room temperature to a mixture of interm. (58) (13.2 g) in DME (140 ml). The mixture was stirred at room temperature overnight. Water was added and the mixture was neutralized with HCl 3N. The precipitate was filtered off, washed with water and with DIPE and dried, yielding 10.75 g (86%) of *N*-[6-bromo-4-(3-chlorophenyl)-1,2-dihydro-2-oxo-8-quinolinyl]acetamide (interm. 59).

10 f) A mixture of interm. (59) (10.75 g), methyl iodide (3.57 ml) and Ag_2CO_3 (16.93 g) in DMF (150 ml) was stirred at 80°C under N_2 flow for 90 minutes. The mixture was allowed to cool to room temperature. Water was added. The mixture was filtered over celite, washed with water and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated, yielding 10.9 g (98%) of *N*-[6-bromo-4-(3-chlorophenyl)-2-methoxy-8-quinolinyl]acetamide (interm. 60).


15 g) Butyllithium (1.6 M in hexanes, 18.5 ml) was added dropwise at -70°C under N_2 flow to a mixture of interm. (60) (5 g) in THF (70 ml). The mixture was stirred at -70°C for 30 minutes, brought to -40°C and cooled again to -70°C. (4-Chlorophenyl) (1-methyl-1*H*-imidazol-5-yl)methanone (6.5 g) was added. The mixture was allowed to warm to room temperature and then hydrolyzed. Ethyl acetate was added. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 95/5/0.1). The pure fraction was collected, evaporated, recrystallized from 2-propanone, ACN and DIPE, yielding 1.3 g (32.5%) of (\pm)-*N*-[4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-2-methoxy-8-quinolinyl]acetamide (interm. 61, mp. 143°C).

25 h) A mixture of interm. (61) (3 g) in HBr (48% in H_2O , 45ml) and 1,4-dioxane (40 ml) was stirred at 80°C for 3 hours. The mixture was cooled to room temperature, poured out on ice, saturated with K_2CO_3 solid and extracted with ethyl acetate. The organic layer was separated, dried, filtered, evaporated and purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 95/5/0.5). The pure fractions were collected and the solvent was evaporated. The residue was taken up in CH_3OH and DIPE. The precipitate was filtered off and dried, yielding 0.4 g (55%) of (\pm)-8-amino-4-(3-chlorophenyl)-6-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-2(1*H*)-quinolinone (interm. 62).

35

Tables I-1 to I-2 list intermediates prepared according to one of the above Examples.


Table I-1 :



| Intm. No. | Ex. No. | -A- | R ¹ | R ² | Physical data |
|-----------|---------|---|-------------------|----------------|---------------|
| 1 | A.6 | -(CH ₂) ₃ - | 3-Cl | H | - |
| 2 | A.6 | -(CH ₂) ₂ - | 3-Br | H | - |
| 3 | A.6 | -(CH ₂) ₂ - | 3-Cl | H | mp. 138°C |
| 4 | A.6 | -(CH ₂) ₂ - | 4-Cl | H | - |
| 5 | A.6 | -(CH ₂) ₂ - | 3-Cl | 4-Cl | - |
| 6 | A.6 | -(CH ₂) ₂ - | 3-CH ₃ | H | - |
| 7 | A.7 | -(CH ₂ [*]) ₂ -O- | 3-Cl | H | - |

5 * : the CH₂ moiety is linked to the nitrogen atom of the 2-quinolinone moiety

Table I-2 :



10

| Intm. No. | Ex. No. | --- | -A- | R ¹ | R ² | R ³ | Physical data |
|-----------|---------|--------|------------------------------------|----------------|----------------|----------------|---------------|
| 8 | A.2 | single | -(CH ₂) ₃ - | 3-Cl | H | 4-Cl | mp. 176°C |
| 9 | A.2 | single | -(CH ₂) ₂ - | H | H | 4-Cl | - |
| 10 | A.2 | single | -(CH ₂) ₂ - | 3-Br | H | 4-Cl | - |
| 11 | A.2 | single | -(CH ₂) ₂ - | 3-Cl | H | 4-Cl | mp. 140°C |

| Intm. No. | Ex. No. | ---- | -A- | R ¹ | R ² | R ³ | Physical data |
|-----------|---------|--------|---|-------------------|----------------|--------------------|---------------|
| 12 | A.2 | single | -(CH ₂) ₂ - | 3-Cl | H | 4-F | - |
| 13 | A.2 | single | -(CH ₂) ₂ - | 3-Cl | H | 3-Cl | - |
| 14 | A.2 | single | -(CH ₂) ₂ - | 3-Cl | 4-Cl | 4-Cl | - |
| 15 | A.2 | single | -(CH ₂) ₂ - | 3-Cl | H | H | - |
| 16 | A.2 | single | -(CH ₂) ₂ - | 3-Cl | H | 4-CH ₃ | - |
| 17 | A.2 | single | -(CH ₂) ₂ - | 3-Cl | H | 2-Cl | - |
| 18 | A.2 | single | -(CH ₂) ₂ - | 3-Cl | H | 4-OCH ₃ | - |
| 19 | A.2 | single | -(CH ₂) ₂ - | 4-Cl | H | 4-Cl | - |
| 20 | A.2 | single | -(CH ₂) ₂ - | 3-CH ₃ | H | 4-Cl | - |
| 21 | A.4 | double | -(CH ₂) ₂ - | H | H | 4-Cl | - |
| 22 | A.4 | double | -(CH ₂) ₂ - | 3-Br | H | 4-Cl | - |
| 23 | A.4 | double | -(CH ₂) ₃ - | 3-Cl | H | 4-Cl | mp. 194°C |
| 24 | A.3 | double | -(CH ₂) ₂ - | 3-Cl | H | 4-Cl | mp. 191°C |
| 25 | A.3 | double | -CH=CH- | 3-Cl | H | 4-Cl | - |
| 26 | A.5 | double | -(CH ₂ [*]) ₂ -O- | 3-Cl | H | 4-Cl | mp. 135°C |
| 27 | A.5 | double | -CH ₂ [*] -O- | 3-Cl | H | 4-Cl | mp. 154°C |
| 28 | A.4 | double | -(CH ₂) ₂ - | 3-Cl | H | 4-F | - |
| 29 | A.4 | double | -(CH ₂) ₂ - | 3-Cl | H | 3-Cl | - |
| 30 | A.4 | double | -(CH ₂) ₂ - | 3-Cl | 4-Cl | 4-Cl | - |
| 31 | A.4 | double | -(CH ₂) ₂ - | 3-Cl | H | H | - |
| 32 | A.4 | double | -(CH ₂) ₂ - | 3-Cl | H | 4-CH ₃ | - |
| 33 | A.4 | double | -(CH ₂) ₂ - | 3-Cl | H | 2-Cl | - |
| 34 | A.4 | double | -(CH ₂) ₂ - | 3-Cl | H | 4-OCH ₃ | - |
| 35 | A.4 | double | -(CH ₂) ₂ - | 4-Cl | H | 4-Cl | - |
| 36 | A.4 | double | -(CH ₂) ₂ - | 3-CH ₃ | H | 4-Cl | - |

* : the CH₂ moiety is linked to the nitrogen atom of the 2-quinolinone moiety

B. Preparation of the final compounds.

5 Example B.1

A solution of 1-methylimidazole (4.55 ml) in THF (200 ml) was cooled to -70°C. Butyllithium (1.6 M in hexanes, 35.9 ml) was added and the mixture was stirred at -70°C for 30 minutes. Triethylsilyl chloride (10.4 ml) was added and the mixture was

allowed to warm to room temperature slowly. The mixture was cooled to -70°C and butyllithium (1.6 M in hexanes 35.9 ml) was added dropwise. The mixture was stirred at -70°C for 1 hour and was then allowed to warm to -15°C . The bath was removed and the mixture was cooled to -70°C . Intermediate (24) (20 g) was added and the mixture was stirred at -70°C for 30 minutes. The mixture was hydrolyzed and extracted with ethyl acetate. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatograph (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 97/3/0.1), yielding 24 g of (\pm)-6-(3-chlorophenyl)-8-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-1,2-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-4-one (comp. 5, mp. 213.6°C).

Example B.2

A mixture of compound 1 (2.5 g) in formamide (10 ml) and acetic acid (20 ml) was stirred at 160°C for 4 hours. The mixture was poured out on ice, basified with an aqueous ammonia solution and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}/\text{NH}_4\text{OH}$ 97/3/0.1). The pure fractions were collected and the solvent was evaporated. The residue was taken up in 2-propanone/DIPE. The precipitate was filtered off and dried, yielding 1 g (41%) of (\pm)-6-(3-chlorophenyl)-8-[(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-1,2-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-4-one monohydrate (comp. 6, mp. 147.0°C).

Example B.3

A mixture of compound 5 (2 g) in thionyl chloride (8 ml) was stirred at room temperature overnight. The solvent was evaporated till dryness. The product was used without further purification, yielding 2.07 g (100%) of (\pm)-8-[chloro(4-chlorophenyl)-(1-methyl-1*H*-imidazol-5-yl)methyl]-6-(3-chlorophenyl)-1,2-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-4-one monohydrochloride (comp. 7).

Example B.4

A mixture of compound 7 (2.07 g) in THF (15 ml) was poured out into an aqueous ammonia solution (40 ml) at room temperature. The mixture was stirred at room temperature for 4 hours, then extracted with DCM and decanted. The organic layer was dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : toluene/2-propanol/ NH_4OH 50/50/1). The pure fractions were collected and the solvent was evaporated. The residue was recrystallized

from CH₂Cl₂/diethyl ether. The precipitate was filtered off and dried, yielding 0.65 g (±)-8-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-6-(3-chlorophenyl)-1,2-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-4-one (comp. 8).

5 Example B.5

Compound 8 (12.4 g) was separated and purified by chiral column chromatography over Chiracel OD (eluent : 100% CH₃OH). Two pure fraction groups were collected. The solvent of the first fraction group was evaporated. The residue was crystallized from 2-propanol (200 ml) and DIPE (200 ml). The precipitate was filtered off and
10 dried, yielding 4.4 g of (A)-8-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-6-(3-chlorophenyl)-1,2-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-4-on (compound 9; $[\alpha]_D^{20} = -27.94^\circ$ (c = 9.1 mg/ml in methanol)).

The solvent of the second fraction group was evaporated. The residue was crystallized from 2-propanol (250 ml) and DIPE (350 ml). The precipitate was filtered off and
15 dried, yielding: 4.1 g of (B)-8-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-6-(3-chlorophenyl)-1,2-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinolin-4-on (compound 10; $[\alpha]_D^{20} = +28.21^\circ$ (c = 9 mg/ml in methanol)).

Example B.6

20 A mixture of intermediate (50) (2.7 g), dibromomethane (3 ml) and potassium carbonate (2.8 g) in DMF (90 ml) was stirred at 80°C for 3 hours. Water was added. The mixture was filtered over celite, washed with water and extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent :
25 CH₂Cl₂/CH₃OH/NH₄OH 96/4/0.2). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from 2-propanone and diethyl ether. The precipitate was filtered off and dried, yielding 0.86g (31%) of (±)-6-(3-chlorophenyl)-8-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-2*H*,4*H*-oxazolo[5,4,3-*ij*]quinolin-4-one (comp. 15).

30

Example B.7

A mixture of compound 6 (1.2 g) and phosphorus sulfide (2.4 g) in pyridine (30 ml) was stirred and refluxed for 6 hours and then poured out into water. The precipitate was filtered off, rinsed abundantly with water, taken up in DCM, dried, filtered and the
35 solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 98/2/0.1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from ACN

and DIPE. The precipitate was filtered off and dried, yielding 0.36 g (29.2%) of (\pm)-6-(3-chlorophenyl)-8-[(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-1,2-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinoline-4-thione (comp. 27).

5 Example B.8

- A mixture of interm. (62) (1.8 g) and ethyl acetimidate (0.9 g) in methanol (40 ml) was stirred and refluxed for 4 hours. The solvent was evaporated till dryness. The residue was taken up in DCM and K₂CO₃ (10% in H₂O). The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column
- 10 chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 95/5/0.5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from DIPE. The precipitate was filtered off and dried, yielding 0.4 g (21.2%) of (\pm)-6-(3-chlorophenyl)-8-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-2-methyl-4*H*-imidazo[4,5,1-*ij*]quinolin-4-one (comp. 30, mp. 170°C).
- 15 In a similar way, (\pm)-6-(3-chlorophenyl)-8-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-2-phenyl-4*H*-imidazo[4,5,1-*ij*]quinolin-4-one (comp. 31) was also prepared.

Example B.9

- 20 A mixture of interm. (62) (2.1 g) and 1,1'-carbonyldiimidazole (4.1) in THF (60 ml) was stirred and refluxed for 3 hours. The mixture was poured out into water and extracted with DCM. The organic layer was separated, washed with water, dried, filtered and the solvent was evaporated till dryness. The residue was purified by column
- 25 chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 90/10/0.5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from CH₃OH and DIPE. The precipitate was filtered off and dried, yielding 0.7 g (31.8%) of (\pm)-6-(3-chlorophenyl)-8-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-4*H*-imidazo[4,5,1-*ij*]quinoline-2,4(1*H*)-dione(comp. 34, mp. 256°C).

30 Example B.10

- A mixture of interm. (62) (2.1 g) in water (21 ml) and sulfuric acid (36 N, 42 ml) was cooled to 5°C on an ice bath. NaNO₂ (3.6 ml; solution 80g/100ml) was added dropwise while the temperature was kept at 5°C. The mixture was stirred for 1 hour on an ice bath, poured out into ice water, alkalinized with a concentrated NH₄OH solution and
- 35 extracted with DCM. The organic layer was separated, dried, filtered and the solvent was evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 97.5/2.5/0.1). The pure fractions were collected and

the solvent was evaporated. The residue was crystallized from 2-propanone and DIPE. The precipitate was filtered off and dried, yielding 0.35 g (16.3%) of (\pm)-6-(3-chlorophenyl)-8-[(4-chlorophenyl)hydroxy(1-methyl-1*H*-imidazol-5-yl)methyl]-4*H*-1,2,3-triazolo[4,5,1-*ij*]quinolin-4-one (comp. 35, mp. 226°C).

Example B.11

A mixture of intermediate (54) (3.4 g) and imidazole (2.01 g) in ACN (40 ml) was stirred and refluxed for 3 hours. The mixture was evaporated and the residue was taken up in DCM. The organic layer was washed with water, dried, filtered off and evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 97/3/0.1). The pure fractions were collected and evaporated. Crystallisation from ethyl acetate and DIPE yielded 1.9 g (65%) (\pm)-7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-2,3-dihydro-1*H*,5*H*-benzo[*ij*]quinolizin-5-one (comp. 36, mp. 195.2°C).

Example B.12

1,1'-Carbonyldiimidazole (4 g) was added at room temperature to a solution of intermediate (53) (5.4 g) in THF (70 ml) and the mixture was stirred at room temperature for 16 hours. Water was added and the mixture was extracted with DCM.

The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 97.5/2.5/0.1). The pure fractions were collected and evaporated. The residue was purified further by column chromatography over silica gel (eluent : cyclohexane/2-propanol/NH₄OH 80/20/0.1). The pure fractions were collected and evaporated. The residue was taken up in diethyl ether and filtered off, yielding 1.3g (22%) of (\pm)-7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-2,3,6,7-tetrahydro-1*H*,5*H*-benzo[*ij*]quinolizin-5-one (comp. 37, mp. 93.6°C).

Example B.13


A mixture of intermediate (48) (2.3 g) and imidazole (1.8 g) in ACN (50 ml) was stirred and refluxed for 4 hours. The solvent was evaporated till dryness. The residue was taken up in DCM, washed with water and decanted. The organic layer was dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH/NH₄OH 98/2/0.1). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from ACN and DIPE. The precipitate was filtered off and dried, yielding 1.3 g of (\pm)-6-

(3-chlorophenyl)-8-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-2*H*,4*H*-oxazolo[5,4,3-*ij*]quinolin-4-one (comp. 52).

Example B.14

- 5 Phosphorus sulfide (6 g) was added to a mixture of compound 38 (3 g) in pyridine (40 ml). The mixture was stirred and refluxed for 6 hours. Ice water was added. The precipitate was filtered off, washed with water and taken up in DCM. The organic layer was separated, dried, filtered and the solvent was evaporated till dryness. The residue was purified by column chromatography over silica gel (eluent : CH₂Cl₂/CH₃OH
- 10 98.5/1.5). The pure fractions were collected and the solvent was evaporated. The residue was crystallized from ACN and DIPE. The precipitate was filtered off and dried, yielding 1.1 g of (±)-6-(3-chlorophenyl)-8-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-1,2-dihydro-4*H*-pyrrolo[3,2,1-*ij*]quinoline-4-thione (comp. 50).
- 15 Tables F-1 and F-3 list the compounds that were prepared according to one of the above Examples.

Table F-1 :



20

| Co. No. | Ex. No. | X | -A- | R ¹ | R ² | R ³ | R ⁴ | R ⁶ | Physical data |
|---------|---------|---|------------------------------------|----------------|----------------|----------------|----------------|-----------------|------------------|
| 1 | B.1 | O | -(CH ₂) ₂ - | H | H | 4-Cl | H | OH | mp. 240°C |
| 2 | B.3 | O | -(CH ₂) ₂ - | H | H | 4-Cl | H | Cl | (2) |
| 3 | B.4 | O | -(CH ₂) ₂ - | H | H | 4-Cl | H | NH ₂ | mp. 218°C |
| 4 | B.1 | O | -(CH ₂) ₂ - | 3-Br | H | 4-Cl | H | OH | mp. 210°C |
| 5 | B.1 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-Cl | H | OH | mp. 213.6°C |
| 6 | B.2 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-Cl | H | H | mp. 147.0°C; (1) |
| 7 | B.3 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-Cl | H | Cl | (2) |


| Co. No. | Ex. No. | X | -A- | R ¹ | R ² | R ³ | R ⁴ | R ⁶ | Physical data |
|---------|---------|---|--|-------------------|----------------|-------------------|----------------|-----------------|--|
| 8 | B.4 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-Cl | H | NH ₂ | mp. 165°C |
| 9 | B.5 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-Cl | H | NH ₂ | (A); |
| 10 | B.5 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-Cl | H | NH ₂ | [α] _D ²⁰ = -27.94° |
| 11 | B.1 | O | -(CH ₂) ₃ - | 3-Cl | H | 4-Cl | H | OH | (B); |
| 12 | B.1 | O | -(CH ₂) ₃ - | 3-Cl | H | 4-Cl | H | OH | [α] _D ²⁰ = +28.21° |
| 13 | B.3 | O | -(CH ₂) ₃ - | 3-Cl | H | 4-Cl | H | Cl | mp. 210°C(dec.) |
| 14 | B.4 | O | -(CH ₂) ₃ - | 3-Cl | H | 4-Cl | H | NH ₂ | mp. 232°C; (2) |
| 15 | B.6 | O | -CH ₂ *-O- | 3-Cl | H | 4-Cl | H | OH | (2) |
| 16 | B.3 | O | -(CH ₂) ₂ -O- | 4-Cl | H | 4-Cl | H | Cl | mp. 190°C |
| 17 | B.1 | O | -(CH ₂ *) ₂ -O- | 3-Cl | H | 4-Cl | H | OH | mp. 196°C |
| 18 | B.4 | O | -(CH ₂ *) ₂ -O- | 3-Cl | H | 4-Cl | H | NH ₂ | (2) |
| 19 | B.1 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-F | H | OH | mp. 252°C |
| 20 | B.3 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-F | H | Cl | mp. 210°C |
| 21 | B.4 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-F | H | NH ₂ | mp. 224°C |
| 22 | B.1 | O | -(CH ₂) ₂ - | 3-Cl | H | 3-Cl | H | OH | (2) |
| 23 | B.1 | O | -(CH ₂) ₂ - | 3-Cl | H | H | H | OH | mp. 235°C |
| 24 | B.1 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-CH ₃ | H | OH | mp. 220°C |
| 25 | B.1 | O | -(CH ₂) ₂ - | 3-Cl | H | 2-Cl | H | OH | mp. 260°C |
| 26 | B.1 | O | -(CH ₂) ₂ - | 3-CH ₃ | H | 4-Cl | H | OH | mp. 245°C |
| 27 | B.7 | S | -(CH ₂) ₂ - | 3-Cl | H | 4-Cl | H | H | mp. 210°C; (1) |
| 30 | B.8 | O | -CH(CH ₃)=N- | 3-Cl | H | 4-Cl | H | OH | mp. 242°C |
| 31 | B.6 | O | -CH(C ₆ H ₅)=N- | 3-Cl | H | 4-Cl | H | OH | mp. 138°C |
| 32 | B.3 | O | -CH(C ₆ H ₅)=N- | 3-Cl | H | 4-Cl | H | Cl | mp. 170°C |
| 33 | B.4 | O | -CH(C ₆ H ₅)=N- | 3-Cl | H | 4-Cl | H | NH ₂ | mp. 176°C |
| 34 | B.9 | O | -CO-NH- | 3-Cl | H | 4-Cl | H | OH | (1) |
| 35 | B.10 | O | -N=N- | 3-Cl | H | 4-Cl | H | OH | mp. 215°C |
| | | | | | | | | | mp. 256°C |
| | | | | | | | | | mp. 226°C |

* : the CH₂ moiety is linked to the nitrogen atom of the 2-quinolinone moiety

(1) : hydrate (1:1)

(2) : hydrochloride (1:1)


Table F-2 :



| Co. No. | Ex. No. | X | -A- | R ¹ | R ² | R ³ | R ⁴ | R ⁶ | Physical data |
|---------|---------|---|------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| 28 | B.1 | O | -(CH ₂) ₂ - | 3-Cl | H | 4-Cl | H | OH | mp. 248°C |
| 29 | B.1 | O | -(CH ₂) ₃ - | 3-Cl | H | 4-Cl | H | OH | (3); mp. 154°C |

5 (3) : ethanedioate (1:1) hydrate (1:1)

Table F-3 :



| Co. No. | Ex. No. | --- | -A- | X | R ¹ | R ² | R ³ | Physical data |
|---------|---------|--------|------------------------------------|---|----------------|----------------|--------------------|---------------|
| 36 | B.11 | double | -(CH ₂) ₃ - | O | 3-Cl | H | 4-Cl | mp. 195.2°C |
| 37 | B.12 | single | -(CH ₂) ₃ - | O | 3-Cl | H | 4-Cl | mp. 93.6°C |
| 38 | B.11 | double | -(CH ₂) ₂ - | O | 3-Cl | H | 4-Cl | mp. 204.1°C |
| 39 | B.13 | double | -(CH ₂) ₂ - | O | 3-Cl | H | H | mp. 200°C |
| 40 | B.13 | double | -(CH ₂) ₂ - | O | 3-Cl | H | 2-Cl | mp. 216°C |
| 41 | B.13 | double | -(CH ₂) ₂ - | O | 3-Cl | H | 3-Cl | mp. 180°C |
| 42 | B.13 | double | -(CH ₂) ₂ - | O | 3-Cl | H | 4-F | mp. 210°C |
| 43 | B.13 | double | -(CH ₂) ₂ - | O | 3-Cl | H | 4-CH ₃ | mp. 210°C |
| 44 | B.13 | double | -(CH ₂) ₂ - | O | 3-Cl | H | 4-OCH ₃ | mp. 120°C |
| 45 | B.13 | double | -(CH ₂) ₂ - | O | 3-Cl | 4-Cl | 4-Cl | mp. 210°C |

| Co. No. | Ex. No. | --- | -A- | X | R ¹ | R ² | R ³ | Physical data |
|---------|---------|--------|---|---|-------------------|----------------|----------------|----------------|
| 46 | B.13 | double | -(CH ₂) ₂ - | O | 4-Cl | H | 4-Cl | mp. 190°C; (1) |
| 47 | B.13 | double | -(CH ₂) ₂ - | O | 3-CH ₃ | H | 4-Cl | mp. 200°C |
| 48 | B.13 | double | -(CH ₂) ₂ - | O | 3-Br | H | 4-Cl | mp. 196°C |
| 49 | B.13 | double | -(CH ₂) ₂ - | O | H | H | 4-Cl | mp. 184°C; (1) |
| 50 | B.14 | double | -(CH ₂) ₂ - | S | 3-Cl | H | 4-Cl | mp. 253°C |
| 51 | B.11 | double | -CH=CH- | O | 3-Cl | H | 4-Cl | mp. 104°C |
| 52 | B.13 | double | -(CH ₂ [*])-O- | O | 3-Cl | H | 4-Cl | mp. 208°C |
| 53 | B.13 | double | -(CH ₂ [*]) ₂ -O- | O | 3-Cl | H | 4-Cl | mp. 180°C |

* : the CH₂ moiety is linked to the nitrogen atom of the 2-quinolinone moiety
 (1) : .ethanedioate (2:3) salt

5 C. Pharmacological example.

Example C.1 : "In Vitro Assay for Inhibition of Farnesyl Protein Transferase" :

Human farnesyl protein transferase was prepared essentially as described (Y. Reiss et al., Methods: A Companion to Methods in Enzymology, vol. 1, 241-245, 1990). Kirsten virus transformed human osteosarcoma (KHOS) cells (American Type Culture Collection, Rockville, MD, USA) grown as solid tumors in nude mice or grown as monolayer cell cultures were used as a source of human enzyme. Briefly, cells or tumors were homogenized in buffer containing 50 mM Tris, 1 mM EDTA, 1 mM EGTA and 0.2 mM phenylmethylsulfonylfluoride (pH 7.5). The homogenates were centrifuged 28,000 x g for 60 min and the supernatants collected. A 30-50% ammonium sulfate fraction was prepared, and the resulting precipitate was resuspended in a small (10 to 20 ml) volume of dialysis buffer containing 20 mM Tris, 1 mM dithiothreitol and 20 μM ZnCl₂. The ammonium sulfate fraction was dialyzed overnight against two changes of the same buffer. The dialyzed material was applied to a 10 x 1 cm Q Fast Flow Sepharose (Pharmacia LKB Biotechnology Inc., Piscataway, NJ, USA) which had been preequilibrated with 100 ml of dialysis buffer supplemented with 0.05 M NaCl. The column was washed with an additional 50 ml of dialysis buffer plus 0.05 M NaCl followed by a gradient from 0.05 M to 0.25 M NaCl prepared in dialysis buffer. The enzyme activity was eluted with a linear gradient of 0.25 to 1.0 M NaCl prepared in the dialysis buffer. Fractions containing 4 to 5 ml volumes of column eluate were collected and analyzed for farnesyl protein transferase

activity. Fractions with enzyme activity were pooled and supplemented with 100 μ M ZnCl_2 . Enzyme samples were stored frozen at -70°C .

5 The activity of farnesyl protein transferase was measured using the Farnesyl
Transferase [^3H] Scintillation Proximity Assay (Amersham International plc., England)
under the conditions specified by the manufacturer. To assay for inhibitors of the
enzyme, 0.20 μCi of the [^3H]-farnesylpyrophosphate substrate and the biotinylated
lamin B peptide substrate (biotin-YRASNRSCAIM) were mixed with test compounds
10 in a reaction buffer consisting of 50 mM HEPES, 30 mM MgCl_2 , 20 mM KCl, 5 mM
dithiothreitol, 0.01% Triton X-100. Test compounds were delivered in a 10 μl volume
of dimethylsulfoxide (DMSO) to achieve concentrations of 1 and 10 $\mu\text{g}/\text{ml}$ in a final
volume of 100 μl . The reaction mixture was warmed to 37°C . The enzyme reaction
was started by adding 20 μl of diluted human farnesyl protein transferase. Sufficient
15 enzyme preparation was added to produce between 4000 to 15000 cpm of reaction
product during the 60 min of reaction incubation at 37°C . Reactions were terminated
by the addition of STOP/scintillation proximity bead reagent (Amersham). The
reaction product [^3H]-farnesyl-(Cys)-biotin lamin B peptide was captured on the
streptavidin linked scintillation proximity bead. The amount of [^3H]-farnesyl-(Cys)-
20 biotin lamin B peptide synthesized in the presence or absence of test compounds was
quantified as cpm by counting on a Wallac Model 1480 Microbeta Liquid Scintillation
Counter. The cpm of product was considered to be farnesyl protein transferase activity.
The protein farnesyl transferase activity observed in the presence of test compound was
normalized to farnesyl transferase activity in the presence of 10% DMSO and expressed
25 as per cent inhibition. In separate studies, some test compounds exhibiting 50% or
greater inhibition of farnesyl protein transferase activity were evaluated for
concentration-dependent inhibition of enzyme activity. The effects of test compounds
in these studies were calculated as IC_{50} (concentration of test compound producing
50% inhibition of enzyme activity) using the LGIC50 computer program written by the
Science Information Division of R. W. Johnson Pharmaceutical Research Institute
30 (Spring House, PA, USA) on a VAX computer.
Compound 36 was found to have a IC_{50} of 21 nM and compound 38 to have a IC_{50} of
15 nM.

Example C.2 : "Ras-Transformed Cell Phenotype Reversion Assay".

35 Insertion of activated oncogenes such as the mutant *ras* gene into mouse NIH 3T3 cells
converts the cells to a transformed phenotype. The cells become tumorigenic, display

anchorage independent growth in semi-solid medium and lose contact inhibition. Loss of contact inhibition produces cell cultures which no longer form uniform monolayers. Rather, the cells pile up into multicellular nodules and grow to very high saturation densities in plastic tissue culture dishes. Agents such as protein farnesyl transferase inhibitors which revert the *ras* transformed phenotype restore the uniform monolayer growth pattern to cells in culture. This reversion is easily monitored by counting the number of cells in tissue culture plates. Transformed cells will achieve higher cell numbers than cells which have reverted to an untransformed phenotype. Compounds which revert the transformed phenotype should produce antitumor effects in tumors bearing *ras* gene mutations.

Method:

Compounds are screened in tissue culture in NIH 3T3 cells transformed by the T24 activated human H-*ras* gene. Cells are seeded at an initial density of 200,000 cells per well (9.6 cm² surface area) in six-well cluster tissue culture plates. Test compounds are immediately added to 3.0 ml cell growth medium in a 3.0 µl volume of DMSO, with a final concentration of DMSO in the cell growth medium of 0.1%. The test compounds are run at concentrations of 5, 10, 50, 100, and 500 nM along with a DMSO treated vehicle control. (In case a high activity is observed at 5 nM, the test compound is tested at even lower concentrations.) The cells are allowed to proliferate for 72 hours. Then the cells are detached in 1.0 ml trypsin-EDTA cell dissociation medium and counted on a Coulter particle counter.

Measurements:

Cell numbers expressed as cells per well are measured using a Coulter Particle Counter.

All cell counts were corrected for the initial cell input density by subtracting 200,000.

Control cell counts = [cell counts from cells incubated with DMSO vehicle - 200,000]

Test compound cell counts = [cell counts from cells incubated with test compound - 200,000].

Test compound %inhibition = $\left[1 - \frac{\text{test compound cell counts}}{\text{control cell counts}} \right] \times 100\%$.

IC₅₀ (i.e. the test compound concentration required to inhibit enzyme activity by 50%) is calculated if sufficient data are available, summarized in table C.2.

Table C.2 :

| Co. No. | IC ₅₀ (nM) |
|---------|-----------------------|
| 1 | 142 |
| 3 | 51 |
| 4 | 50 |
| 5 | 7.8 |
| 6 | 32 |
| 8 | 6.4 |
| 10 | 3.2 |
| 12 | 66 |
| 14 | 7.3 |
| 15 | 48 |
| 17 | 63 |
| 18 | > 500 |
| 19 | 240 |
| 21 | 18 |
| 22 | 352 |
| 23 | 442 |
| 24 | 12 |
| 25 | 37 |
| 26 | 21 |
| 27 | 37.1 |
| 28 | 100 |
| 29 | 184 |
| 30 | 373 |
| 31 | > 500 |
| 33 | 73.1 |
| 34 | > 500 |
| 35 | > 500 |
| 40 | > 500 |
| 41 | > 500 |
| 44 | 353 |
| 45 | > 500 |
| 48 | > 500 |
| 49 | > 500 |
| 51 | > 500 |
| 53 | > 500 |

Example C.3 : "Farnesyl Protein Transferase Inhibitor Secondary Tumor Model".

The enzyme farnesyl protein transferase catalyzes the covalent attachment of a farnesyl moiety derived from farnesyl pyrophosphate to the oncogene product p21^{ras}. This directs p21^{ras} to attach to plasma membranes. Once attached to plasma membranes, mutant or oncogenic forms of p21^{ras} will provide a signal for the transformation and uncontrolled growth of malignant tumor cells. Therefore, inhibitors of protein farnesyltransferase will prevent the membrane attachment of p21^{ras} and inhibit growth of *ras*-transformed tumors.

Nude mice are inoculated with 1×10^6 of T24 activated human H-*ras* gene transformed NIH 3T3 fibroblast cells (T24 cells), subcutaneously in the inguinal region. After three days to allow tumors to become established, treatment with test compounds is begun via the oral route. The test compounds are dissolved in a 20% β -cyclodextrin in 0.1 N HCl solution and administered orally as 0.1 ml of compound solution per 10 g mouse body weight. Routinely used doses are 6.25, 12.5 and 25 mg/kg. Body weights and tumor sizes are monitored during the ensuing 15 days of treatment. At the end of treatment, animals are sacrificed and tumors are weighed.

The "mean vehicle treated tumor weight" is defined as the mean tumor weight from 10 to 15 mice treated with the test compound.

The "mean tumor weight" is defined as the mean tumor weight from 10 to 15 mice not treated with the test compound.


$$\% \text{ Reduction final tumor weight} = \left[1 - \frac{\text{mean tumor weight}}{\text{mean vehicle treated tumor weight}} \right] \times 100\%.$$

Table C.3 :

| Co. No. | Dose | % reduction final tumor weight |
|---------|----------------------------|--------------------------------|
| 8 | 6.25 mg/kg <i>bid, po</i> | 41 % |
| | 12.25 mg/kg <i>bid, po</i> | 44 % |
| | 25 mg/kg <i>bid, po</i> | 49 % |

Claims

1. A compound of formula (I)



a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof, wherein

the dotted line represents an optional bond;

X is oxygen or sulfur;

-A- is a bivalent radical of formula

-CH=CH- (a-1),

-CH₂-CH₂- (a-2),

-CH₂-CH₂-CH₂- (a-3),

-CH₂-O- (a-4),

-CH₂-CH₂-O- (a-5),

-CH₂-S- (a-6),

-CH₂-CH₂-S- (a-7),

-CH=N- (a-8),

-N=N- (a-9), or

-CO-NH- (a-10);

wherein optionally one hydrogen atom may be replaced by C₁₋₄alkyl or Ar¹;

R¹ and R² each independently are hydrogen, hydroxy, halo, cyano, C₁₋₆alkyl, trihalomethyl, trihalomethoxy, C₂₋₆alkenyl, C₁₋₆alkyloxy, hydroxyC₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyloxy, C₁₋₆alkyloxycarbonyl, aminoC₁₋₆alkyloxy, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy, Ar², Ar²-C₁₋₆alkyl, Ar²-oxy, Ar²-C₁₋₆alkyloxy; or

when on adjacent positions R¹ and R² taken together may form a bivalent radical of formula

-O-CH₂-O- (b-1),

-O-CH₂-CH₂-O- (b-2),

-O-CH=CH- (b-3),

-O-CH₂-CH₂- (b-4),



-O-CH₂-CH₂-CH₂- (b-5), or

-CH=CH-CH=CH- (b-6);

R³ and R⁴ each independently are hydrogen, halo, cyano, C₁₋₆alkyl, C₁₋₆alkyloxy, Ar³-oxy, C₁₋₆alkylthio, di(C₁₋₆alkyl)amino, trihalomethyl, trihalomethoxy, or when on adjacent positions R³ and R⁴ taken together may form a bivalent radical of formula

- 5 -O-CH₂-O- (c-1),
 -O-CH₂-CH₂-O- (c-2), or
 -CH=CH-CH=CH- (c-3);

R⁵ is a radical of formula



- 10 wherein R¹³ is hydrogen, halo, Ar⁴, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyloxy, C₁₋₆alkylthio, amino, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylS(O)C₁₋₆alkyl or C₁₋₆alkylS(O)₂C₁₋₆alkyl;

R¹⁴ is hydrogen, C₁₋₆alkyl or di(C₁₋₄alkyl)aminosulfonyl;

- 15 R⁶ is hydrogen, hydroxy, halo, C₁₋₆alkyl, cyano, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, cyanoC₁₋₆alkyl, aminoC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkylthioC₁₋₆alkyl, aminocarbonyl-C₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, C₁₋₆alkylcarbonylC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, mono- or di(C₁₋₆alkyl)aminoC₁₋₆alkyl, Ar⁵,
 20 Ar⁵-C₁₋₆alkyloxyC₁₋₆alkyl; or a radical of formula

- O-R⁷ (e-1),
 -S-R⁷ (e-2), or
 -N-R⁸R⁹ (e-3);

wherein

- 25 R⁷ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, Ar⁶, Ar⁶-C₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, or a radical of formula -Alk-OR¹⁰ or -Alk-NR¹¹R¹²;

R⁸ is hydrogen, C₁₋₆alkyl, Ar⁷ or Ar⁷-C₁₋₆alkyl;

- 30 R⁹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylaminocarbonyl, Ar⁸, Ar⁸-C₁₋₆alkyl, C₁₋₆alkylcarbonyl-C₁₋₆alkyl, Ar⁸-carbonyl, Ar⁸-C₁₋₆alkylcarbonyl, aminocarbonylcarbonyl, C₁₋₆alkyloxyC₁₋₆alkylcarbonyl, hydroxy, C₁₋₆alkyloxy, aminocarbonyl, di(C₁₋₆alkyl)aminoC₁₋₆alkylcarbonyl, amino, C₁₋₆alkylamino,

C₁₋₆alkylcarbonylamino, or a radical or formula -Alk-OR¹⁰ or -Alk-NR¹¹R¹²;

wherein Alk is C₁₋₆alkanediyl;

R¹⁰ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, hydroxyC₁₋₆alkyl, Ar⁹ or Ar⁹-C₁₋₆alkyl;

R¹¹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkylcarbonyl, Ar¹⁰ or Ar¹⁰-C₁₋₆alkyl;


R¹² is hydrogen, C₁₋₆alkyl, Ar¹¹ or Ar¹¹-C₁₋₆alkyl; and

Ar¹ to Ar¹¹ are each independently selected from phenyl; or phenyl substituted with halo, C₁₋₆alkyl, C₁₋₆alkyloxy or trifluoromethyl.

2. A compound according to claim 1 wherein the dotted line represents an optional bond; X is O or S; R¹ and R² are each independently selected from hydrogen, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, trihalomethyl or trihalomethoxy; R³ and R⁴ are each independently selected from hydrogen, halo, C₁₋₆alkyl, C₁₋₆alkyloxy, trihalomethyl or trihalomethoxy; R⁵ a radical of formula (d-1) wherein R¹³ is hydrogen or R⁵ is a radical of formula (d-2) wherein R¹³ is hydrogen or C₁₋₆alkyl and R¹⁴ is hydrogen or C₁₋₆alkyl; R⁶ is hydrogen, hydroxy, haloC₁₋₆alkyl, hydroxyC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkyloxycarbonylC₁₋₆alkyl, or a radical of formula -NR⁸R⁹ wherein R⁸ is hydrogen or C₁₋₆alkyl and R⁹ is hydrogen, C₁₋₆alkyl, C₁₋₆alkyloxy or C₁₋₆alkyloxyC₁₋₆alkylcarbonyl.
3. A compound according to any of claims 1 to 2 wherein X is oxygen; the dotted line represents a bond; R¹ is 3-halo; R² is hydrogen; R³ is 4-halo; R⁴ is hydrogen; R⁵ a radical of formula (d-1) wherein R¹³ is hydrogen or R⁵ is a radical of formula (d-2) wherein R¹³ is hydrogen and R¹⁴ is C₁₋₄alkyl; R⁶ is hydrogen, halo, hydroxy or amino; and -A- is (a-1), (a-2) or (a-3).
4. A compound according to claim 1 wherein the compound is
 7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-2,3-dihydro-1*H*,5*H*-benzo[*ij*]quinolizin-5-one;
 7-(3-chlorophenyl)-9-[(4-chlorophenyl)-1*H*-imidazol-1-ylmethyl]-1,2-dihydro-4*H*-pyrrolo[3,2,*1-ij*]quinoline-4-one;
 8-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-6-(3-chlorophenyl)-1,2-dihydro-4*H*-pyrrolo[3,2,*1-ij*]quinolin-4-one; or


8-[amino(4-chlorophenyl)(1-methyl-1*H*-imidazol-5-yl)methyl]-6-(3-chlorophenyl)-2,3-dihydro-1*H*,5*H*-benzo[*ij*]quinolizin-5-one; a stereoisomeric form or a pharmaceutically acceptable acid addition salt thereof.

5. A pharmaceutical composition comprising a pharmaceutically acceptable carrier, and as active ingredient a therapeutically effective amount of a compound as described in any one of claims 1 to 4.
6. A process for preparing a pharmaceutical composition as claimed in claim 5 wherein a therapeutically effective amount of a compound as claimed in any one of claims 1 to 4 is intimately mixed with a pharmaceutically acceptable carrier.
7. A compound of formula (VI)



- 15 an acid addition salt or a stereochemically isomeric form thereof, wherein X, R¹, R² and -A- are as defined in claim 1.

8. A compound of formula (II)




- 20 an acid addition salt or a stereochemically isomeric form thereof, wherein the dotted line represents an optional bond; X, R¹, R², R³, R⁴ and -A- are as defined in claim 1.


- 25 9. A compound according to any one of claims 1 to 4 for use as a medicine.

10. A process for preparing a compound as claimed in claim 1, wherein


- a) an intermediate ketone of formula (II) is reacted with an intermediate of formula (III-1) or (III-2) in the presence of a suitable strong base and in the presence an appropriate silanederivative, optionally followed by removal of a protective group PG;



- b) compounds of formula (I-a), defined as compounds of formula (I) wherein R⁶ is hydroxy, are converted to compounds of formula (I-c) wherein R⁶ is halo, optionally followed by treatment with an intermediate of formula H-NR⁸R⁹ yielding compounds of formula (I-d);




- c) an intermediate of formula (XVII) is *N*-alkylated with an intermediate of formula (XVIII) in a reaction-inert solvent and, optionally in the presence of a suitable base;



5

- d) an intermediate of formula (XVI) is *N*-alkylated with a compound of formula (XIX);



10

wherein in the above reaction schemes the dotted line and the radicals X, R¹, R², R³, R⁴, R⁵, R⁶, R⁸, R⁹ and R¹³ and -A- are as defined in claim 1, W is an appropriate leaving group and Y is carbon or sulfur;


15

- e) or, compounds of formula (I) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (I) is converted into a pharmaceutically acceptable acid addition salt, or conversely, an acid addition salt of a compound of formula (I) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

20

11. A process for preparing a compound of formula (VI) as claimed in claim 7 wherein an intermediate of formula (IV) is cyclized in the presence of polyphosphoric acid (PPA),

25




wherein in the above reaction schemes the radicals X, R¹, R² and -A- are as defined in claim 1;


or, compounds of formula (VI) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (VI) is converted into a pharmaceutically acceptable acid addition salt, or conversely, an acid addition salt of a compound of formula (VI) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

12. A process for preparing an intermediate compound of formula (II) as claimed in claim 8 wherein


a) an intermediate of formula (VI) is treated with an intermediate of formula (V) in the presence of polyphosphoric acid (PPA);



b) or, an intermediate of formula (IV) with an intermediate of formula (V) in the presence of polyphosphoric acid (PPA);



- c) intermediates of formula (II-a), defined as intermediates of formula (II) wherein the dotted line does not represent a bond, can be converted into intermediates of formula (II-b), defined as an intermediate of formula (II) wherein the dotted line represents a bond, by oxidation



wherein in the above reaction schemes the radicals X, R¹, R², R³, R⁴ and -A- are as defined in claim 1;

- d) or, compounds of formula (II-a) are converted into each other following art-known transformation reactions; or if desired; a compound of formula (II-a) is converted into a pharmaceutically acceptable acid addition salt, or conversely, an acid addition salt of a compound of formula (II-a) is converted into a free base form with alkali; and, if desired, preparing stereochemically isomeric forms thereof.

INTERNATIONAL SEARCH REPORT

Inte [redacted] cation No
PCT/EP 98/01296

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D471/06 C07D498/06 A61K31/47 //(C07D471/06,221:00,
209:00),(C07D498/06,263:00,221:00)

According to International Patent Classification(IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C07D A61K A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| A | WO 96 20200 A (JANSSEN PHARMACEUTICA NV ; VENET MARC GASTON (FR); MABIRE DOMINIQUE) 4 July 1996 see page 9; claims | 1,5 |
| A | WO 93 25548 A (GLAXO GROUP LTD ;CHERRY PETER CLIVE (GB); FOXTON MICHAEL WALTER (G) 23 December 1993 see page 4; claims | 1,5 |
| A | EP 0 371 564 A (JANSSEN PHARMACEUTICA NV) 6 June 1990 cited in the application see page 32; tables 5A-8A | 1,5 |
| A | EP 0 371 559 A (JANSSEN PHARMACEUTICA NV) 6 June 1990 see page 12; claim 1 | 1,5 |

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 July 1998

Date of mailing of the international search report

17/07/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 98/01296

| C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT | | |
|--|--|-----------------------|
| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
| A | US 4 014 883 A (FRYER RODNEY IAN ET AL) 29 March 1977 see abstract; claim 1 ----- | 1,5 |
| X | GB 1 394 373 A (PFIZER LTD.) 14 May 1975 see example 35 ----- | 7 |

INTERNATIONAL SEARCH REPORT

information on patent family members

International Publication No

PCT/EP 98/01296

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| WO 9620200 A | 04-07-1996 | AU 4436296 A | 19-07-1996 |
| | | CA 2207268 A | 04-07-1996 |
| | | EP 0800524 A | 15-10-1997 |
| | | FI 972794 A | 27-06-1997 |
| | | HR 950616 A | 31-10-1997 |
| | | NO 973029 A | 27-06-1997 |
| | | PL 321041 A | 24-11-1997 |
| WO 9325548 A | 23-12-1993 | AU 675950 B | 27-02-1997 |
| | | AU 4326093 A | 04-01-1994 |
| | | CA 2138392 A | 23-12-1993 |
| | | CN 1089264 A | 13-07-1994 |
| | | CZ 9403194 A | 18-10-1995 |
| | | EP 0574992 A | 22-12-1993 |
| | | EP 0646114 A | 05-04-1995 |
| | | FI 945907 A | 15-12-1994 |
| | | HU 72311 A | 29-04-1996 |
| | | JP 7507782 T | 31-08-1995 |
| | | MX 9303574 A | 31-01-1994 |
| | | NO 944888 A | 16-02-1995 |
| | | NZ 253135 A | 29-01-1997 |
| | | US 5578630 A | 26-11-1996 |
| EP 0371564 A | 06-06-1990 | AT 124941 T | 15-07-1995 |
| | | AU 620946 B | 27-02-1992 |
| | | AU 4564689 A | 07-06-1990 |
| | | CA 2002864 A | 29-05-1990 |
| | | CN 1042912 A,B | 13-06-1990 |
| | | CN 1106004 A,B | 02-08-1995 |
| | | CN 1106005 A,B | 02-08-1995 |
| | | CY 1920 A | 07-03-1997 |
| | | DE 68923430 D | 17-08-1995 |
| | | DK 599489 A | 30-05-1990 |
| | | ES 2088889 T | 01-10-1996 |
| | | GR 3017351 T | 31-12-1995 |
| | | HK 118196 A | 12-07-1996 |
| | | HU 9500329 A | 30-10-1995 |
| | | IE 67803 B | 01-05-1996 |
| | | JP 2223579 A | 05-09-1990 |
| | | NO 174509 B | 07-02-1994 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/01296

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| EP 0371564 | A | | PT 92448 A,B | 31-05-1990 |
| | | | SU 1780536 A | 07-12-1992 |
| | | | US 5037829 A | 06-08-1991 |
| | | | US 5441954 A | 15-08-1995 |
| | | | US 5612354 A | 18-03-1997 |
| | | | US 5185346 A | 09-02-1993 |
| | | | US 5268380 A | 07-12-1993 |
| | | | US 5028606 A | 02-07-1991 |
| | | | US 5151421 A | 29-09-1992 |
| <hr/> | | | | |
| EP 0371559 | A | 06-06-1990 | AT 112681 T | 15-10-1994 |
| | | | AU 630579 B | 29-10-1992 |
| | | | AU 1071692 A | 19-03-1992 |
| | | | AU 623454 B | 14-05-1992 |
| | | | AU 4564889 A | 07-06-1990 |
| | | | CA 2002859 A | 29-05-1990 |
| | | | CY 1867 A | 05-04-1996 |
| | | | DE 68918809 D | 17-11-1994 |
| | | | DE 68918809 T | 23-03-1995 |
| | | | DK 599589 A | 30-05-1990 |
| | | | EP 0609963 A | 10-08-1994 |
| | | | ES 2065369 T | 16-02-1995 |
| | | | HK 114895 A | 21-07-1995 |
| | | | IE 63877 B | 14-06-1995 |
| | | | IL 92487 A | 29-12-1994 |
| | | | JP 10095782 A | 14-04-1998 |
| | | | JP 2752200 B | 18-05-1998 |
| | | | JP 3020273 A | 29-01-1991 |
| | | | PT 92449 A,B | 31-05-1990 |
| | | | US 5420147 A | 30-05-1995 |
| | | | US 5500435 A | 19-03-1996 |
| | | | US 5157046 A | 20-10-1992 |
| | | | US 5342957 A | 30-08-1994 |
| <hr/> | | | | |
| US 4014883 | A | 29-03-1977 | CA 1012147 A | 14-06-1977 |
| | | | FI 88474 A | 11-03-1975 |
| | | | SE 7403950 A | 11-03-1975 |
| <hr/> | | | | |
| GB 1394373 | A | 14-05-1975 | HK 62776 A | 15-10-1976 |
| | | | HK 62876 A | 15-10-1976 |

INTERNATIONAL SEARCH REPORT

information on patent family members

International Publication No

PCT/EP 98/01296

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| GB 1394373 A | | JP 922889 C | 22-09-1978 |
| | | JP 49041539 A | 18-04-1974 |
| | | JP 52048176 B | 08-12-1977 |
| | | US 3917838 A | 04-11-1975 |
| | | US 4008325 A | 15-02-1977 |
| <hr/> | | | |